文献速递胸部肿瘤

二甲双胍联合EGFR-TKI治疗EGFR突变肺腺癌的2期随机试验

Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2019-11-14

这项在墨西哥开展的开放标签2期随机试验纳入139例晚期EGFR突变肺腺癌患者,比较EGFR-TKI联合二甲双胍与单用EGFR-TKI的疗效。

要点

  • 二甲双胍联合EGFR-TKI较单用TKI显著改善PFS(HR 0.60)。
  • 联合组中位OS亦显著延长(31.7 vs 17.5个月)。
  • 结果支持开展3期安慰剂对照研究。

核心结论

  • 在晚期EGFR突变肺腺癌患者中,二甲双胍联合标准EGFR-TKI治疗较单用EGFR-TKI显著改善无进展生存期。

研究设计与样本

  • 开放标签、随机、2期试验,在墨西哥城Instituto Nacional de Cancerología开展。
  • 纳入139例18岁以上、组织学确诊IIIB-IV期伴激活EGFR突变的肺腺癌患者,随机分入EGFR-TKI组(n=70)或EGFR-TKI联合二甲双胍组(n=69)。

关键数值与推荐

  • 二甲双胍用法为500 mg每日两次,与标准剂量厄洛替尼、阿法替尼或吉非替尼联用。
  • 治疗持续至出现不可耐受毒性或撤回知情同意。

临床怎么用

  • 对于晚期EGFR突变肺腺癌患者,在标准EGFR-TKI治疗基础上加用二甲双胍可能改善PFS和OS。
  • 该结果尚需3期安慰剂对照试验验证后方可改变临床实践。

局限性

  • 为开放标签2期试验,样本量有限(共139例),非安慰剂对照。
  • 研究仅在墨西哥单中心开展,外推性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Metformin hydrochloride is emerging as a repurposed anticancer drug. Preclinical and retrospective studies have shown that it improves outcomes across a wide variety of neoplasms, including lung cancer. Particularly, evidence is accumulating regarding the synergistic association between metformin and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). OBJECTIVE: To assess the progression-free survival (PFS) in patients with advanced lung adenocarcinoma who received treatment with EGFR-TKIs plus metformin compared with those who received EGFR-TKIs alone. DESIGN, SETTING, AND PARTICIPANTS: Open-label, randomized, phase 2 trial conducted at the Instituto Nacional de Cancerología (INCan), Mexico City, Mexico. Eligible patients were 18 years or older, had histologically confirmed stage IIIB-IV lung adenocarcinoma with an activating EGFR mutation. INTERVENTIONS: Patients were randomly allocated to receive EGFR-TKIs (erlotinib hydrochloride, afatinib dimaleate, or gefitinib at standard dosage) plus metformin hydrochloride (500 mg twice a day) or EGFR-TKIs alone. Treatment was continued until occurrence of intolerable toxic effects or withdrawal of consent. MAIN OUTCOMES AND MEASURES: The primary outcome was PFS in the intent-to-treat population. Secondary outcomes included objective response rate, disease control rate, overall survival (OS), and safety. RESULTS: Between March 31, 2016, and December 31, 2017, a total of 139 patients (mean [SD] age, 59.4 [12.0] years; 65.5% female) were randomly assigned to receive EGFR-TKIs (n = 70) or EGFR-TKIs plus metformin (n = 69). The median PFS was significantly longer in the EGFR-TKIs plus metformin group (13.1; 95% CI, 9.8-16.3 months) compared with the EGFR-TKIs group (9.9; 95% CI, 7.5-12.2 months) (hazard ratio, 0.60; 95% CI, 0.40-0.94; P = .03). The median OS was also significantly longer for patients receiving the combination therapy (31.7; 95% CI, 20.5-42.8 vs 17.5; 95% CI, 11.4-23.7 months; P = .02). CONCLUSIONS AND RELEVANCE: To our knowledge, this is the first study to prospectively show that the addition of metformin to standard EGFR-TKIs therapy in patients with advanced lung adenocarcinoma significantly improves PFS. These results justify the design of a phase 3, placebo-controlled study. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03071705.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Arrieta O, Barrón F, Padilla MS, et al. Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 31486833. doi:10.1001/jamaoncol.2019.2553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。